| Biomarker ID | 371 |
| PMID | 18767028 |
| Year | 2008 |
| Biomarker | Her-2/neu |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.41 (95% CI: 1.00 – 5.80) |
| Effect on Pathways | Pathways Include:-Prolactin activation of MAPK signaling,Alpha-6 beta-1 and alpha-6 beta-4 integrin signaling,Non-small cell lung cancer,Adherens junction cell adhesion,ATM-dependent DNA damage response |
| Experiment | Progression Vs No Progression |
| Type of Biomarker | Prognostic |
| Cohort | 124 cases with prostate cancer were chosen for the study. 14 patients were removed from the analysis due to the absense of biomarekers for study. Rest were divided into clinical stages and some cases (T1b, T1c, T3a) with very low frequencies were removed and a total of 105 patients were chosen for study. 43 patients had no progression, and 62 had progression. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.049 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Dichotomized Variable; Multivariate Analysis |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ERBB2 |